Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine TumorDevata S. · Kim E.J.
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich., USA Corresponding Author
Edward J. Kim
C409 Med Inn
1500 E. Medical Center Drive, SPC 5843
Ann Arbor, MI 48109 (USA)
Pancreatic neuroendocrine tumors (PNETs) are relatively rare tumors that arise in the endocrine cells of the pancreas. Historically, somatostatin analogues have been used in this disease primarily for symptom control and, to a limited extent, disease stability. More recently, sunitinib and everolimus have been approved for advanced stage PNETs based on a survival benefit. However, both agents have a <10% actual response rate and cause nontrivial side effect profiles that limit duration of therapy. In locally advanced disease, there is a paucity of data to support an optimal neoadjuvant approach with the expectation of down-staging to allow for curative resection. We describe in this case a young woman who was successfully down-staged using a chemotherapy regimen of capecitabine and temozolomide with minimal toxicity.
© 2012 S. Karger AG, Basel
Published online: November 20, 2012
Number of Print Pages : 5
Number of Figures : 1,
Case Reports in Oncology
Vol. 5, No. 3, Year 2012 (Cover Date: September - December)
Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: 1662-6575 (Print), eISSN: 1662-6575 (Online)
For additional information: http://www.karger.com/CRO